Biodesix, Inc.
NASDAQ: BDSX0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Global Market
- Sector
- Healthcare
- Industry
- Medical - Diagnostics & Research
- CEO
- Scott Hutton
- Employees
- 273
- Headquarters
- Boulder, United States
- IPO year
- 2020
- Market cap
- $152.0M
- Website
- https://www.biodesix.com
Loading BDSX…
Loading profile data…Frequently asked questions about BDSX
What does Biodesix, Inc. (BDSX) do?
Biodesix, Inc. is a data-driven diagnostic solutions provider operating across the United States. Its primary focus includes a comprehensive suite of blood-based lung tests, marketed as the Nodify Lung Nodule Risk Assessment (which includes Nodify XL2 and Nodify CDT). These assessments enable clinicians to evaluate the risk of lung cancer in pat...
Where does BDSX trade?
Biodesix, Inc. (BDSX) trades on the NASDAQ Global Market.
What sector is BDSX in?
Biodesix, Inc. (BDSX) operates in the Healthcare sector, specifically in the Medical - Diagnostics & Research industry.
Who is the CEO of Biodesix, Inc.?
Scott Hutton is the chief executive officer of Biodesix, Inc. (BDSX).
Where is Biodesix, Inc. headquartered?
Biodesix, Inc. is headquartered in United States.
Does BDSX pay a dividend?
Biodesix, Inc. (BDSX) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did BDSX go public?
Biodesix, Inc. (BDSX) completed its initial public offering in 2020.